S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.83%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.83%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.83%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
S&P 500   3,298.46 (+1.60%)
DOW   27,173.96 (+1.34%)
QQQ   271.56 (+2.32%)
AAPL   112.28 (+3.75%)
MSFT   207.82 (+2.28%)
FB   254.82 (+2.12%)
GOOGL   1,439.06 (+1.14%)
AMZN   3,095.13 (+2.49%)
TSLA   407.34 (+5.04%)
NVDA   514.95 (+4.26%)
BABA   271.09 (+0.50%)
CGC   14.17 (-0.70%)
GE   6.11 (+0.83%)
MU   49.14 (-0.67%)
AMD   78.06 (+2.95%)
T   28.04 (+0.00%)
F   6.51 (-2.25%)
ACB   5.05 (-2.88%)
GILD   62.25 (+0.00%)
NFLX   482.88 (+2.07%)
DIS   124.00 (+1.23%)
BAC   23.49 (+0.64%)
BA   156.03 (+6.83%)
Log in
NASDAQ:MDVN

Medivation Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$81.44
0.00 (0.00 %)
(As of 09/29/2016)
Add
Today's Range
$81.44
Now: $81.44
$81.44
50-Day Range N/A
52-Week Range
$26.41
Now: $81.44
$81.48
VolumeN/A
Average Volume3.55 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.
Read More
Medivation logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.80 out of 5 stars


Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:MDVN
CUSIP58501N10
Phone+1-415-5433470

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive MDVN News and Ratings via Email

Sign-up to receive the latest news and ratings for MDVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Medivation (NASDAQ:MDVN) Frequently Asked Questions

How were Medivation's earnings last quarter?

Medivation Inc (NASDAQ:MDVN) posted its earnings results on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.02. The biopharmaceutical company had revenue of $206 million for the quarter, compared to analysts' expectations of $214.52 million. The company's revenue for the quarter was up 17.4% on a year-over-year basis. During the same period last year, the business posted $0.58 EPS.
View Medivation's earnings history
.

Who are some of Medivation's key competitors?

What other stocks do shareholders of Medivation own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medivation investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Array Biopharma (ARRY), Freeport-McMoRan (FCX) and Celgene (CELG).

What is Medivation's stock symbol?

Medivation trades on the NASDAQ under the ticker symbol "MDVN."

What is Medivation's stock price today?

One share of MDVN stock can currently be purchased for approximately $81.44.

What is Medivation's official website?

The official website for Medivation is www.medivation.com.

How can I contact Medivation?

Medivation's mailing address is 525 Market St Fl 36, SAN FRANCISCO, CA 94105-2747, United States. The biopharmaceutical company can be reached via phone at +1-415-5433470.

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.